These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

862 related items for PubMed ID: 8918500

  • 1. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM, Rosti G, Visani G, Gherlinzoni F, Miggiano MC, Fortuna A, Zinzani P, Tura S.
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [Abstract] [Full Text] [Related]

  • 2. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM, Fortuna A, Fogli M, Gherlinzoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC, Tura S.
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [Abstract] [Full Text] [Related]

  • 3. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 4. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM, Pandite AN, Beveridge RA, Geller RB, Schuster MW, Anderson JE, LeMaistre CF, Ahmed T, Granena A, Keating A, Fernandez Ranada JM, Stiff PJ, Tabbara I, Longo W, Copelan EA, Nichols C, Smith A, Topolsky DL, Bierman PJ, Lebsack ME, Lange M, Garrison L.
    J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
    Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, Cabanillas FF, Hagemeister FB, Souza LM.
    J Clin Oncol; 1989 Dec; 7(12):1791-9. PubMed ID: 2479719
    [Abstract] [Full Text] [Related]

  • 6. Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients.
    Lemoli RM, Fortuna A, Fogli M, Rosti G, Gherlinzoni F, Visani G, Catani L, Gozzetti A, Tura S.
    Acta Haematol; 1996 Dec; 95(3-4):164-70. PubMed ID: 8677737
    [Abstract] [Full Text] [Related]

  • 7. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
    Cortelazzo S, Viero P, Bellavita P, Rossi A, Buelli M, Borleri GM, Marziali S, Bassan R, Comotti B, Rambaldi A.
    J Clin Oncol; 1995 Apr; 13(4):935-41. PubMed ID: 7535843
    [Abstract] [Full Text] [Related]

  • 8. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.
    Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH, Piñeiro LA, Cooper BW, DiCesare J, Campion M.
    Blood; 1994 Oct 01; 84(7):2151-7. PubMed ID: 7919329
    [Abstract] [Full Text] [Related]

  • 9. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep 01; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 10. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH.
    J Clin Oncol; 1997 Jan 01; 15(1):5-10. PubMed ID: 8996118
    [Abstract] [Full Text] [Related]

  • 11. Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
    Stahel RA, Jost LM, Honegger H, Betts E, Goebel ME, Nagler A.
    J Clin Oncol; 1997 May 01; 15(5):1730-5. PubMed ID: 9164179
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M, Couture F, Kovacs M, Saragosa R, McCrae J, Brandwein J, Huebsch L, Beauregard-Zollinger L, Keating A.
    Exp Hematol; 1993 Mar 01; 21(3):405-410. PubMed ID: 8440338
    [Abstract] [Full Text] [Related]

  • 13. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, Rifkin R, Bierman PJ, Lynch JC, Weisenburger DD, Kessinger A, Armitage JO.
    J Clin Oncol; 2002 May 01; 20(9):2344-52. PubMed ID: 11981006
    [Abstract] [Full Text] [Related]

  • 14. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T.
    Bone Marrow Transplant; 1995 Feb 01; 15(2):261-6. PubMed ID: 7539668
    [Abstract] [Full Text] [Related]

  • 15. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
    Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L.
    J Clin Oncol; 1992 Sep 01; 10(9):1452-9. PubMed ID: 1517788
    [Abstract] [Full Text] [Related]

  • 16. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
    Fay JW, Bernstein SH.
    Semin Oncol; 1996 Apr 01; 23(2 Suppl 4):22-7. PubMed ID: 8600545
    [Abstract] [Full Text] [Related]

  • 17. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
    Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A.
    Lancet; 1996 Feb 10; 347(8998):353-7. PubMed ID: 8598700
    [Abstract] [Full Text] [Related]

  • 18. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A, Ferrando F, Garuti A, Basta P, Gonella R, Stura P, Mela GS, Sessarego M, Gobbi M, Patrone F.
    J Clin Oncol; 1999 Apr 10; 17(4):1296. PubMed ID: 10561192
    [Abstract] [Full Text] [Related]

  • 19. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A, Jacky E, Fey M, Platzer E.
    J Clin Oncol; 1994 Sep 10; 12(9):1931-8. PubMed ID: 7521907
    [Abstract] [Full Text] [Related]

  • 20. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M, Jawniak D, Kotwica K, Wach M, Mańko J, Gorący A, Klimek P, Mazurkiewicz E, Jarosz P, Hus M.
    Transplant Proc; 2014 Oct 10; 46(8):2882-4. PubMed ID: 25380941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.